



0027 925

17-Cycloalkylmethyl-6-methylene-morphinane derivatives

Morphine is a well known narcotic analgesic having the structural formula:



The compounds of this invention are structurally related to morphine and are named according to the morphinan system of nomenclature using the morphinan nucleus which is shown below:



The numbering and stereochemical placement of atoms in the morphinan system is the same as that depicted for morphine. A dashed line is used to represent a covalent bond projecting below the plane of a reference atom while a wedged or heavily accented line signifies a covalent bond above such plane. The compounds of this invention have the same stereochemical placement of atoms as depicted for morphine in those positions where the stereochemistry is not depicted by a dashed or wedged line.

Morphine and its structurally related relatives are used primarily as analgesics. While extremely effective for the relief of moderate to severe pain these compounds are narcotic and most possess dependence-inducing ability and produce other side effects such as emesis, constipation, sweating, respiratory depression and myosis which make them less than ideal analgesics. It is impossible to predict, based on structure alone, whether a particular morphine-like compound will act as an analgesic (agonist), a narcotic antagonist or possess a combination of these properties since very minute structural modifications in the molecule result in significant changes in pharmacological activity. A compound with the appropriate profile of analgesic (agonist) and narcotic antagonist actions has potential for treatment of moderate to severe pain without the liability of drug dependence or drug abuse. Those compounds which are pure analgesics are useful in the treatment of acute pain.


The morphinan nucleus has been modified by the introduction of a carbonyl group into the 6-position and the conversion of the 3-hydroxy group to 3-methoxy.

In this regard, Sawa et. al., report the preparation of 7,8-didehydro-3-methoxy-17-methyl-morphinan-6-one in Tetrahedron 20: 2247 (1964). Sawa et. al., also report narcotic antagonist activity for certain 17-allyl, 17-dimethylallyl or 17-cyclopropylmethyl substituted 3-hydroxy-morphinan-6-one compounds in U.S. Patent No. 3,654,280 issued April 4, 1972. German Offenlegungsschrift 29 00 644 discloses 8-alkyl substituted 3-hydroxy- or 3-methoxy-morphinan-6-one compounds which possess mixed analgesic/narcotic antagonist activity.

15


0027925

The preparation of the 6-methylene derivative of the narcotic antagonists naloxone and naltrexone has been reported by Hahn et al in *J. Med. Chem.*, 18, 259 (1975) to provide compounds of the formula:




20 where R is either cyclopropylmethyl or allyl and which are disclosed as being useful as narcotic antagonists.

Fishman et al., disclose in U.S. Patent 3,896,226 a narcotic antagonist composition of the formula:



40 where R₁ is allyl or cyclopropylmethyl, R₂ is hydrogen or hydroxy and R₃ is hydroxy or methoxy.
J. Fishman discloses in U.S. Patent 3,162,639 6-desoxy-14-hydroxy-dihydromorphine derivatives of the formula:




60 where R is —OCH₃ or OH. These compounds are described as being useful as narcotic, analgesic and sedative agents.

The present invention involves a series of 17-cycloalkylmethyl-3-hydroxy-or-methoxy-6-methylene-morphinanes characterized by the formula:


0027 925

(16)



wherein R_1 and R_3 are H or methyl and R_2 is cyclopropylmethyl or cyclobutylmethyl.

The 6-methylene morphinan compounds of the present invention are prepared by reacting, in an inert solvent and under an inert atmosphere, methylenetriphenylphosphorane with a 6-keto morphinan 20 of the formula:



wherein R_1 , R_2 and R_3 are as previously defined. The preparation of the 6-keto morphinan precursors is fully described in German Offlegungsschrift No. 29 00 644 and considered to be prior art.

The compounds of this invention are useful as analgesics and as mixed analgesics/narcotic 40 antagonists. In addition, a particular compound of this series (TR—5379 Example IV) was found to have a steeper dose-response curve and a more potent morphine antagonist action than its corresponding 6-keto analog. Furthermore, this compound did not substitute for morphine in drug dependent rats or monkeys thereby indicating an unexpected pharmacological difference when compared to the 6-keto compound having similar substituents.

45 The preparation and pharmacology of the compounds of the present invention is further illustrated by the following examples in which Example V is a comparative example:

Example I

17-cyclopropylmethyl-3-methoxy-8 β -methyl-6-methylene-morphinane (TR—5412)

50 A solution of methylenetriphenylphosphorane was prepared from sodium hydride (14.4 mmole) and methyltriphenylphosphonium bromide (5.14 g, 14.4 mmole) in dimethyl sulfoxide (30 ml) under an argon atmosphere. To this was added a solution of 17-cyclopropylmethyl-3-methoxy-8 β -methyl-morphinan-6-one (2.04 g, 6 mmole) dissolved in dimethyl sulfoxide (20 ml) and the reaction mixture stirred at 75°C in an oil bath for 1 hour.

55 The cooled solution was diluted with ice and concentrated NH_4OH and extracted with three portions of toluene. The combined toluene extracts were washed four times with water, dried and evaporated to a crude residue. The residue was chromatographed over Silica Gel G (400 g) using 20:1 chloroform-methanol as the eluent. Fractions were combined on the basis of thin layer chromatography to give 1.60 g (80%) of the desired product as a crystalline solid. 60 Recrystallization from ether-hexane gave pure TR—5412, mp 91—93°. NMR(CDCl_3): δ 7.17—6.56, 3H, multiplet, aromatic; 4.67, 2H, broad singlet, methylene; 3.80, 3H, singlet, CH_3O —; 0.93, 3H, unsymmetrical doublet, 8 β — CH_3 ; 0.8—0.7, cyclopropyl protons.

65 Anal. Calcd. for $\text{C}_{23}\text{H}_{31}\text{NO}$: C, 81.85; H, 9.26; N, 4.15.
Found: C, 82.22; H, 9.29; N, 4.12.

17

0027925

Example II

17-Cyclopropylmethyl-3-hydroxy-8 β -methyl-6-methylene-morphinan (TR—5413)

A solution of methylenetriphenylphosphorane (14.4 mmole) in dimethyl sulfoxide (30 ml) was prepared under argon as described above. To this was added a solution of 17-cyclopropylmethyl-3-hydroxy-8 β -methylmorphinan-6-one (1.95 g, 6 mmole) in dimethyl sulfoxide. Processing as described above gave a residue which was chromatographed to give 406 mg (20.4%) of the product as a crystalline solid. Recrystallisation from ethanol gave pure TR—5413, mp. 231—233°.

Anal. Calcd. for $C_{22}H_{29}NO$: C, 81.69; H, 9.04; N, 4.33.
Found: C, 81.81; H, 9.39; N, 4.16.

Example III

17-cyclobutylmethyl-3-methoxy-8 β -methyl-6-methylene-morphinan Hydrochloride (TR—5377)

To a solution of methylenetriphenylphosphorane (14.4 mmole) in dimethyl sulfoxide (30 ml) prepared in the usual fashion was added a solution of 17-cyclobutylmethyl-3-methoxy-8 β -methylmorphinan-6-one. The reaction was heated at 75° for 2 hours under an atmosphere of nitrogen. Workup followed by chromatography gave the free base of TR—5377 as a foam. This was converted to the HCl salt which was crystallized from toluene to give 860 mg (37%) of TR—5377, mp. 221—224°.

Anal.: Calcd for $C_{24}H_{33}NO \cdot HCl$: C, 74.30, H, 8.83; N, 3.61.
Found: C, 74.62; H, 8.69; N, 3.56.

Example IV

17-Cyclobutylmethyl-3-hydroxy-8 β -methyl-6-methylene morphinan (TR—5379)

A solution of methylenetriphenylphosphorane was prepared from sodium hydride (14.4 mmole) and methyltriphenylphosphonium bromide (5.14 g, 14.4 mmole) in dimethyl sulfoxide (30 ml) under an argon atmosphere. To this was added a solution of 17-cyclobutylmethyl-3-hydroxy-8 β -methylmorphinan-6-one (free base of Tr—5257, 2.02 g, 6 mmole) in dimethyl sulfoxide (20 ml) and the reaction mixture stirred at 80° in an oil bath for one hour. The cooled solution was diluted with ice and concentrated NH_4OH and extracted with three portions of toluene. The combined toluene extracts were washed with four portions of water, dried and evaporated to crude residue. This residue was chromatographed over Silica Gel G (400 g) using 20:1 chloroform-methanol containing 0.5% concentrated NH_4OH as the eluant. Fractions were combined on the basis of thin layer chromatography to give 1.65 g (82%) of the desired product as a crystalline solid. Recrystallization from ether-hexane gave analytically pure product, mp 165—169°.

Anal. Calcd. for $C_{23}H_{31}NO$: C, 81.85; H, 9.26; N, 4.15.
Found: C, 82.01, H, 9.08; N, 3.92.

Example V

17-Cyclobutylmethyl-3-hydroxy-8 β -methylmorphinan-6-one Tartrate (TR—5257)

To a stirred solution of *d*-tartaric acid (16.09, 106 mmole) in ethanol (100 ml) was added dropwise a solution of 17-cyclobutylmethyl-3-hydroxy-8 β -methylmorphinan-6-one (TR—5130-free base, 32.0 g, 94 mmole) in ethanol (100 ml). After several minutes of stirring, a white solid began to precipitate. The slurry was stirred at room temperature for several hours and then kept in the cold overnight. The solid was collected, washed with cold ethanol followed by ether and dried at atmospheric pressure and 115°C for one hour to give 32.0 g (69%) of TR—5257 as a white powder, mp. 210—213° dec.

Anal. Calcd. for $C_{22}H_{29}NO_2 \cdot C_4H_6O_6$: C, 63.79; H, 7.21; N, 2.86.
Found: C, 63.91; H, 7.25, N, 2.77.

Example VI

17-Cyclobutylmethyl-3-hydroxy-6-methylene-morphinan Hydrochloride Acetone Solvate (TR—5566)

Reaction of 17-cyclobutylmethyl-3-hydroxy-morphinan-6-one (3.0 g, 9.2 mmole) with methylenetriphenylphosphorane (4 equivalents, 36.8 mmole) followed by chromatography of the residue gave 2.6 g (87%) of the free base of TR—5566 as a foam. The hydrochloride salt of TR—5566 was first crystallized from ethyl acetate and then acetone to give pure TR—5566, mp 155° (foams). The presence of acetone was confirmed by nuclear magnetic resonance spectroscopy of TR—5566 in dimethyl sulfoxide- d_6 .

Anal. Calcd. for $C_{22}H_{29}NO \cdot HCl \cdot C_3H_6O$: C, 71.83; H, 8.68; N, 3.35.
Found: C, 71.96; H, 8.55; N, 3.30

(18)

Example VII

17-Cyclopropylmethyl-3-hydroxy-6-methylene-morphinan (TR—5609)

Reaction 17-cyclopropylmethyl-3-hydroxy-morphinan-6-one (1.58 g, 5 mmole) with methylene-triphenylphosphorane (20 mmole) in dimethyl sulfoxide gave a crude residue which was chromatographed using 10:1 chloroform-methanol containing 1% concentrated ammonium hydroxide. Pure fractions were pooled to give 909 mg (58%) of TR—5609 which crystallized from ethanol to give 532 mg of analytically pure TR—5609, mp 220—223°.

Anal. Calcd. for $C_{21}H_{27}NO$: C, 81.51; H, 8.79; N, 4.53.

Found: C, 81.44; H, 8.80; N, 4.30.

Example VIII

17-Cyclobutylmethyl-3-methoxy-6-methylene-morphinan Tartrate Ethanol Solvate (TR—5610)

Reaction of 17-cyclobutylmethyl-3-methoxy-morphinan-6-one (3.39 g, 10 mmole) with methylenetriphenylphosphorane (40 mmole) in dimethyl sulfoxide gave a residue which was chromatographed using 30:1 chloroform-methanol containing 0.5% concentrated ammonium hydroxide. Fractions which contained only the desired product were pooled to give 866 mg (26%) of the free base of TR—5610 as a foam. This was converted to the *d*-tartrate salt which was crystallized from ethanol to give pure Tr—5610, mp 88—91°.

Anal. Calcd. for $C_{23}H_{31}NO \cdot C_4H_6O_6 \cdot C_2H_5OH$: C, 65.27; H, 8.12; N, 2.62.

Found: C, 65.73; H, 7.92; N, 2.51.

PHARMACOLOGICAL EVALUATION

The compounds whose preparation are disclosed in the foregoing examples were screened to determine the following biological activities:

(A) Analgesic effects upon mice (acetic acid writhing test).

(B) Narcotic antagonist activity in rats (modified rat tail flick test).

TEST A

Acetic Acid Mouse Writhing Test

The analgesic effects of the test compounds were determined in mice by use of the acetic acid writhing test described by B. A. Whittle, Brit. J. Pharmacol., 22: 246 (1964). In this test at least three groups of 5 male CD—1 mice each were given subcutaneous doses of the test drug dissolved in distilled water. In all cases 0.4 milliliters of a 0.5% V/V acetic acid in distilled water solution was administered intraperitoneally 15 minutes post drug. The number of writhes in a 20 minute interval beginning 5 minutes after the acetic acid injection were determined and compared with the number of writhes in a control group which had received only acetic acid.

Percent inhibition of writhing was calculated as:

$$\% \text{ inhibition} = \left[\frac{\text{No. Control Writhes} - \text{No. Treated Writhes}}{\text{No. Control Writhes}} \right]$$

The ED_{50} dose, i.e., the dose required to reduce the number of writhes by 50%, was determined graphically from a plot of % inhibition as a probit versus log dose. Confidence limits of 95% were calculated on the basis of those results falling in the range 16—84% inhibition. See Litchfield, J. T. and Wilcoxon, F., J. Pharmacol. Exp. Ther., 96, 99—113 (1949).

TEST B

Evaluation of Narcotic Antagonist Activity

The narcotic antagonist effect of the test compound was determined by a modification of the rat tail flick procedure of Harris and Pierson (J. Pharmacol. Exp. Ther., 143:141 [1964]).

Male albino Wistar rats (100—120 g) were used for this study. A rat's tail is so placed so as to cover a photocell. Heat is applied by a lamp in a reflector with a timer being connected to the lamp and photocell so that the timer goes on when the light is turned on and is turned off when the photocell is uncovered. A rheostat, incorporated into a heating lamp is used to adjust the intensity of the light falling on the tail of the rat such that the rat's control reaction time is from two to four seconds. Animals with a control reaction time outside this range are rejected. The rheostat adjustment is made only if a significant proportion (1 out of every 10 rats) of the reaction times are outside the range of two to four seconds. Groups of 5 rats were used, and two control times were determined at 60 and 30 minutes prior to subcutaneous injection of the drug. A ten second cutoff time is employed; if the rat does not flick its tail in 10 seconds it is removed from the heat source.

At least thirty minutes after the last control run the test drug was given intraperitoneally. This was

followed ten minutes later by an ED_{50} dose of morphine subcutaneously. The animals were retested at 20 minutes after the morphine injection. Control animals were given vehicle and morphine only. The data were calculated as follows:

$$\% \text{Effect (E)} = \left[\frac{\text{MRT}^* (\text{Treated}) - \text{MRT} (\text{Control}) \times 100}{10 - \text{MRT} (\text{Control})} \right]$$


$$\% \text{Antagonism} = \left[\frac{\text{E (morphine control)} - \text{E (Drug treated)} \times 100}{\text{E (morphine control)}} \right]$$

*MRT is defined as mean reaction time.

The data were plotted on log-probit paper and AD_{50} values, i.e., the does required to inhibit the effect of morphine by 50% within 95% confidence limits, were determined by the method of Litchfield and Wilcoxon.

The results obtained using the foregoing procedures are set out in Table I where IA means inactive at the does indicated.

TABLE I



Compound	Ex	R ₁	R ₂	R ₃	ED ₅₀ (mg/kg)	AD ₅₀ (mg/kg)
TR-5412	I	CH ₃	CPM	CH ₃	3.20	3.80
TR-5413	II	H	CPM	CH ₃	1.70	0.29
TR-5377	III	CH ₃	CBM	CH ₃	6.42	5.50
TR-5379	IV	H	CBM	CH ₃	0.18	0.83
* TR-5257	V	H	CBM	CH ₃	0.14	1.22
TR-5566	VI	H	CBM	H	0.09	>10
TR-5609	VII	H	CPM	H	0.38	0.115
TR-5610	VIII	CH ₃	CBM	H	1.60	IA @10

CPM = cyclopropylmethyl
CBM = cyclobutylmethyl
* 6-keto compound

TEST C

Substitution Studies in Physically Morphine Dependent Rats

Rats were made physically dependent by continuous infusion of morphine through an indwelling intraperitoneal cannula as has been described (D. G. Teiger, *J. Pharmacol. Exp. Ther.*, 190 408, 1974). Then one day substitution of either TR—5257 or TR—5379 was studied. Both drugs were infused at the rate of 125 mg/kg/day. Table II shows the change in body weights for both groups during this period of drug substitution for morphine. TR—5257 appeared to prevent the marked loss in weight observed in the morphine controls. There were, however, marked withdrawal symptoms during this period (Table III). The results obtained with TR—5379 are similar except that the initial loss in weight was closer to that seen with morphine. TR—5379 clearly does not substitute for morphine in rats at the doses used. The results with TR—5257 are ambiguous, with indication of partial substitution in this instance.

TABLE II

			Mean % Change in Weight From Termination of Morphine Infusion					
DRUG	DOSE	N	+ 6 hr	+ 1 day*	+ 30 hr	+ 2 days	+ 3 days	+ 4 days
TR-5257	125 mg/kg/day for 1 day	8	-6.1 ±2.9	-7.5 ±2.1	-2.64 ±1.52	-1.4 ±2.4	-0. ±3.1	+2.7 ±3.9
TR-5379	125 mg/kg/day for 1 day	6	-15.1 ±0.9	-15.8 ±2.1	-11.3 ±2.02	-4.5 ±2.2	-0.2 ±2.4	—
Morphine	See Schedule Below	8	—	-16.8 ±1.3	—	-12.7 ±1.9	-7.8 ±2.3	-1.6 ±4.6

* Test drug infusion stopped here.

Animals were infused with morphine according to the following schedule

50 mg/kg/day for 1 day
100 mg/kg/day for 1 day
200 mg/kg/day for 4 days

0027 925

TABLE III
INCIDENCE OF SIDE EFFECTS

5	TR-5257	
	+6 hr*	8/8 — Pilo erection 6/8 — Wet dog shakes 4/8 — Diarrhea 1/8 — Aggressive
10	+24 hr	4/8 — Pilo erection 1/4 — Tremors
15	± 30 hr	4/8 — Pilo erection
	TR-5379	
20	+6 hr*	6/6 — Pilo erection 4/6 — Diarrhea 1/6 — Aggressive
25	+24 hr	6/6 — Pilo erection 2/6 — Diarrhea
	+30 hr	4/6 — Pilo erection 2/6 — Diarrhea


*Post termination of morphine infusion and during test drug infusion.

Morphinan type compounds which possess both agonist and narcotic antagonist activity are of special interest because they can be used to treat pain without the liability of drug dependence in an individual to whom they are administered. The term "individual" is used herein to mean a human being or an experimental animal that is a model for a human being. The dose to be administered to achieve the desired result, i.e., the effective dose, may vary from individual to individual but is readily determined by one skilled in the art without undue experimentation.

The compounds of the present invention form pharmacologically active addition salts with organic and inorganic acids. Typical acid addition salts are the tartrate, hydrobromide, hydrochloride and maleate. The hydrochloride is preferred. The compounds of the present invention may be administered by known, conventional methods of therapeutic administration such as intravenous, parenteral, buccal, rectal or oral. Dose forms for the administration of these compounds can be prepared by methods recognized in the pharmaceutical sciences.

Claims for the Contracting States: BE CH LI DE FR GB IT NL SE

1. 17-cycloalkylmethyl-3-hydroxy or methoxy-6-methylene-morphinanes of the formula:



wherein R₁ and R₃ are H or methyl and R₂ is cyclopropylmethyl or cyclobutylmethyl.

2. A compound according to Claim 1 wherein R₁ is CH₃, R₂ is cyclopropylmethyl and R₃ is CH₃.



(2)

0027925

TABLE III

INCIDENCE OF SIDE EFFECTS

5	<u>TR—5257</u>	
	<u>+6 hr*</u>	8/8 — Pilo erection 6/8 — Wet dog shakes 4/8 — Diarrhea 1/8 — Aggressive
10		
	<u>+24 hr</u>	4/8 — Pilo erection 1/4 — Tremors
15		
	<u>+ 30 hr</u>	4/8 — Pilo erection
	<u>TR—5379</u>	
20	<u>+6 hr*</u>	6/6 — Pilo erection 4/6 — Diarrhea 1/6 — Aggressive
25	<u>+24 hr</u>	6/6 — Pilo erection 2/6 — Diarrhea
	<u>+30 hr</u>	4/6 — Pilo erection 2/6 — Diarrhea


*Post termination of morphine infusion and during test drug infusion.

Morphinan type compounds which possess both agonist and narcotic antagonist activity are of special interest because they can be used to treat pain without the liability of drug dependence in an individual to whom they are administered. The term "individual" is used herein to mean a human being or an experimental animal that is a model for a human being. The dose to be administered to achieve the desired result, i.e., the effective dose, may vary from individual to individual but is readily determined by one skilled in the art without undue experimentation.

The compounds of the present invention form pharmacologically active addition salts with organic and inorganic acids. Typical acid addition salts are the tartrate, hydrobromide, hydrochloride and maleate. The hydrochloride is preferred. The compounds of the present invention may be administered by known, conventional methods of therapeutic administration such as intravenous, parenteral, buccal, rectal or oral. Dose forms for the administration of these compounds can be prepared by methods recognized in the pharmaceutical sciences.

Claims for the Contracting States: BE CH LI DE FR GB IT NL SE

1. 17-cycloalkylmethyl-3-hydroxy or methoxy-6-methylene-morphinanes of the formula:



wherein R_1 and R_3 are H or methyl and R_2 is cyclopropylmethyl or cyclobutylmethyl.

2. A compound according to Claim 1 wherein R_1 is CH_3 , R_2 is cyclopropylmethyl and R_3 is CH_3 .




22

0027 925


3. A compound according to Claim 1 wherein R_1 is H, R_2 is cyclopropylmethyl and R_3 is methyl.
4. A compound according to Claim 1 wherein R_1 is CH_3 , R_2 is cyclobutylmethyl and R_3 is methyl.
5. A compound according to Claim 1 wherein R_1 is H, R_2 is cyclobutylmethyl and R_3 is methyl.
6. A compound according to Claim 1 wherein R_1 is CH_3 , R_2 is cyclopropylmethyl and R_3 is H.
7. A compound according to Claim 1 wherein R_1 is H, R_2 is cyclopropylmethyl and R_3 is H.
8. A compound according to Claim 1 wherein R_1 is CH_3 , R_2 is cyclobutylmethyl and R_3 is H.
9. A compound according to Claim 1 wherein R_1 is H, R_2 is cyclobutylmethyl and R_3 is H.
10. The compounds of Claim 1 in the form of their non-toxic pharmaceutically acceptable, acid addition salts.

Claims for the Contracting State: AT

1. A process for the production of 17-cycloalkylmethyl-3-hydroxy or methoxy-6-methylene-morphinanes of the formula



wherein R_1 and R_3 are H or methyl and R_2 is cyclopropylmethyl or cyclobutylmethyl, characterised in that a 6-keto morphinan of the formula



wherein R_1 , R_2 and R_3 are as stated above is reacted in an inert solvent and under an inert atmosphere with methylenetriphenylphosphorane.

2. A process according to claim 1 wherein R_1 is CH_3 , R_2 is cyclopropylmethyl and R_3 is CH_3 .
3. A process according to Claim 1 wherein R_1 is H, R_2 is cyclopropylmethyl and R_3 is methyl.
4. A process according to Claim 1 wherein R_1 is CH_3 , R_2 is cyclobutylmethyl and R_3 is methyl.
5. A process according to Claim 1 wherein R_1 is H, R_2 is cyclobutylmethyl and R_3 is methyl.
6. A process according to Claim 1 wherein R_1 is CH_3 , R_2 is cyclopropylmethyl and R_3 is H.
7. A process according to Claim 1 wherein R_1 is H, R_2 is cyclopropylmethyl and R_3 is H.
8. A process according to Claim 1 wherein R_1 is CH_3 , R_2 is cyclobutylmethyl and R_3 is H.
9. A process according to Claim 1 wherein R_1 is H, R_2 is cyclobutylmethyl and R_3 is H.
10. A process according to Claim 1 wherein the product is reacted with non-toxic pharmaceutically acceptable acids.




23

0 027 925

Patentansprüche für die Vertragsstaaten: BE CH LI DE FR GB IT NL SE

1. 17-Cycloalkylmethyl-3-hydroxy- oder -methoxy-6-methylen-morphinane der Formel



worin R_1 und R_3 Wasserstoff oder Methyl und R_2 Cyclopropylmethyl oder Cyclobutylmethyl bedeuten.

2. Verbindung gemäss Anspruch 1, worin R_1 CH_3 , R_2 Cyclopropylmethyl und R_3 CH_3 bedeutet.

3. Verbindung gemäss Anspruch 1, worin R_1 H, R_2 Cyclopropylmethyl und R_3 Methyl bedeutet.

4. Verbindung gemäss Anspruch 1, worin R_1 CH_3 , R_2 Cyclobutylmethyl und R_3 Methyl bedeutet.

5. Verbindung gemäss Anspruch 1, worin R_1 H, R_2 Cyclobutylmethyl und R_3 Methyl bedeutet.

6. Verbindung gemäss Anspruch 1, worin R_1 CH_3 , R_2 Cyclopropylmethyl und R_3 H bedeutet.

7. Verbindung gemäss Anspruch 1, worin R_1 H, R_2 Cyclopropylmethyl und R_3 H bedeutet.


8. Verbindung gemäss Anspruch 1, worin R_1 CH_3 , R_2 Cyclobutylmethyl und R_3 H bedeutet.

9. Verbindung gemäss Anspruch 1, worin R_1 H, R_2 Cyclobutylmethyl und R_3 H bedeutet.

10. Verbindungen gemäss Anspruch 1 in Form von deren nicht-toxischen, pharmazeutisch annehmbaren Säureadditionssalzen.

Patentansprüche für den Vertragsstaat: AT

1. Verfahren zur Herstellung von 17-Cycloalkylmethyl-3-hydroxy- oder methoxy-6-methylen-morphinanen der Formel




worin R_1 und R_3 H oder Methyl und R_2 Cyclopropylmethyl oder Cyclobutylmethyl bedeuten, dadurch gekennzeichnet, dass man ein 6-Keto-morphinan der Formel



0027 925


24



- 15 worin R_1 , R_2 und R_3 die vorher angegebenen Bedeutungen haben, in einem inerten Lösungsmittel und unter einer inerten Atmosphäre mit Methylentriphenylphosphoran umgesetzt.
2. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 CH_3 , R_2 Cyclopropylmethyl und R_3 CH_3 bedeutet.
- 20 3. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 H, R_2 Cyclopropylmethyl und R_3 Methyl bedeutet.
4. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 CH_3 , R_2 Cyclobutylmethyl und R_3 Methyl bedeutet.
5. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 H, R_2 Cyclobutylmethyl und R_3 Methyl bedeutet.
- 25 6. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 CH_3 , R_2 Cyclopropylmethyl und R_3 H bedeutet.
7. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 H, R_2 Cyclopropylmethyl und R_3 H bedeutet.
- 30 8. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 CH_3 , R_2 Cyclobutylmethyl und R_3 H bedeutet.
9. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass R_1 H, R_2 Cyclobutylmethyl und R_3 H bedeutet.
10. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass man das Produkt mit nicht-toxischen, pharmazeutisch annehmbaren Säuren umgesetzt.
- 35

Revendications pour les Etats contractants: BE CH LI DE FR GB IT NL SE

40 1. 17-cycloalkylmethyl-3-hydroxy ou méthoxy-6-méthylène-morphinanes de formule:



- 55 dans laquelle R_1 et R_3 représentent H ou un groupe méthyle et R_2 est un groupe cyclopropylméthyle ou cyclobutylméthyle.
- 60 2. Composé suivant la revendication 1, dans lequel R_1 est le groupe CH_3 , R_2 est le groupe cyclopropylméthyle et R_3 est le groupe CH_3 .
3. Composé suivant la revendication 1, dans lequel R_1 représente H, R_2 est le groupe cyclopropylméthyle et R_3 est le groupe méthyle.
- 65 4. Composé suivant la revendication 1, dans lequel R_1 est le groupe CH_3 , R_2 est le groupe cyclobutylméthyle et R_3 est le groupe méthyle.



25

0027925

5. Composé suivant la revendication 1, dans lequel R_1 est H, R_2 est le groupe cyclobutylméthyle et R_3 est le groupe méthyle.

6. Composé suivant la revendication 1, dans lequel R_1 est le groupe CH_3 , R_2 est le groupe cyclopropylméthyle et R_3 est H.

7. Composé suivant la revendication 1, dans lequel R_1 est H, R_2 est le groupe cyclopropylméthyle et R_3 est H.


8. Composé suivant la revendication 1, dans lequel R_1 est le groupe CH_3 , R_2 est le groupe cyclobutylméthyle et R_3 est H.

9. Composé suivant la revendication 1, dans lequel R_1 est H, R_2 est le groupe cyclobutylméthyle et R_3 est H.

10. Composés suivant la revendication 1, sous la forme de leurs sels d'addition d'acides non toxiques pharmaceutiquement acceptables.


Revendications pour l'Etat contractant: AT

1. Procédé de préparation de 17-cycloalkylméthyl-3-hydroxy ou méthoxy-6-méthylène-morphinanes de formule



dans laquelle

R_1 et R_3 représentent H ou un groupe méthyle et R_2 est un groupe cyclopropylméthyle ou cyclobutylméthyle caractérisé en ce qu'on met en présence une 6-kétomorphinane de formule



dans laquelle

R_1 , R_2 et R_3 représentent les groupes précités, avec un méthyle-triphényle-phosphorane en atmosphère inerte.

2. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente CH_3 , R_2 cyclopropylméthyle et R_3 CH_3 .

3. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente H, R_2 cyclopropylméthyle et R_3 méthyle.

4. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente CH_3 , R_2 cyclobutylméthyle et R_3 méthyle.

5. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente H, R_2 cyclobutylméthyle et R_3 méthyle.



26

0027 925

6. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente CH_3 , R_2 cyclopropylméthyle et R_3 H.
7. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente H, R_2 cyclopropylméthyle et R_3 H.
8. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente CH_3 , R_2 cyclobutylméthyle et R_3 H.
9. Procédé suivant la revendication 1, caractérisé en ce que R_1 représente H, R_2 cyclobutylméthyle et R_3 H.
10. Procédé suivant la revendication 1, caractérisé en ce que l'on met le produit en présence avec des acides non-toxiques pharmaceutiquement acceptables.

15

20

25

30

35

40

45

50

55

60

65